Therefore, the role of P-gp expression in tumor infiltrating immune cells should be more carefully studied in future to determine the potential application of combinatorial strategy of P-gp inhibitors with immune-checkpoint therapy (anti-CTLA4/anti-PD1) (119, 120). This evidence concerns the gene PGP and neoplasm.